Safety Alerts & Recalls
What does this mean?
If you use one of these CFC inhalers, talk with your doctor or other healthcare professional about switching to a medicine that does not contain CFCs. You cannot be sure how long you will be able to buy your CFC inhaler because manufacturers may stop making them before the last day they can be sold. For example, the manufacturers of two of the inhalers, Alupent Inhalation Aerosol and Tilade Inhaler, have already stopped making these drugs. If you have an inhaler after the last day the inhaler can be sold, you may continue to use it.
To see some of the FDA-approved treatments for asthma and COPD, you can visit the FDA Web page titled "Drug Treatments for Asthma and Chronic Obstructive Pulmonary Disease that Do Not Use Chlorofluorocarbons": http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm082370.htm
If you have any questions about your inhalers or your treatment for your lung condition, please follow up with your doctor or other healthcare professional.
Asthma and COPD Inhalers That Contain Ozone-depleting CFCs to be Phased Out; Alternative Treatments Available
On April 13, 2010, the Food and Drug Administration (FDA) announced that seven metered dose inhalers, including Tilade, that contain chlorofluorocarbons (CFCs) are being phased out in the United States. These inhalers contain ozone-depleting chlorofluorocarbons (CFCs), which are propellants that move medication out of the inhaler and into the lungs of patients. The seven CFC inhalers are used for the treatment of asthma, chronic obstructive pulmonary disease (COPD), or both. Alternative medications that do not contain CFCs are available.
Dates for the phase-out of each CFC inhaler have been set. For Tilade Inhaler (nedocromil), made by King Pharmaceuticals, the last date for sale is June 14, 2010. After this date, this CFC inhaler cannot be made, dispensed, or sold in the United States.
For a complete list of the seven metered dose inhalers being phased out and more information about the phase out, please visit: more information here and